Conduit Pharmaceuticals enters AI analytics deal for AstraZeneca assets; issues 2.26M shares

CDT Equity Inc.

Entered additional agreement with Sarborg for AI analysis of AZD1656, AZD5658, AZD5904 clinical data to identify repurposing opportunities.
Agreement term six months, total consideration $2.0M (cash or stock at company's election).
Issued 1,853,933 shares to satisfy ~$1.65M of fees; also issued 410,113 shares for consulting services.
Company had 9,549,800 shares outstanding as of March 31, 2025.
Aim is to re-evaluate failed endpoints from AstraZeneca trials to identify benefited patient subgroups.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.